接受腹腔內化學治療卵巢癌患者的症狀困擾與照護

Nursing Care for Ovarian Cancer Patients with Intraperitoneal Chemotherapy

10.6224/JN.62.1.87

盧玉嬴(Yu-Ying Lu)；周如芬(Ju-Fen Chou)；曹麗英(Lee-Ing Tsao)；梁淑媛(Shu-Yuan Liang)；吳淑芳(Shu-Fang Wu)

卵巢癌 ； 減積手術 ； 腹腔內化學治療 ； ovarian cancer ； debulking ； intraperitoneal chemotherapy

護理雜誌

62卷1期（2015 / 02 / 01）

87 - 91

繁體中文

卵巢癌素有「沉默殺手」之稱，高居女性癌症死亡率之首位。卵巢癌標準治療為減積手術輔以鉑藥物之化學治療，以期延長病人的存活期。美國婦科腫瘤學會之臨床研究顯示接受減積手術後輔以靜脈合併腹腔內化學治療之卵巢癌個案其平均生存率以及平均無惡化生存時間均高於僅接受靜脈化學治療之個案，成為治療卵巢癌一項新的選擇方式。然而腹腔內化學治療費用較高、副作用大加上導管相關的併發症，成為此項治療的一大挑戰。本文提供臨床照護人員對於腹腔內化學治療可能產生的毒性副作用及併發症之認識，作為照護腹腔內化學治療患者之參考指引。

Ovarian cancer, known as a ＂silent killer＂, is the leading cause of gynecologic cancer death. Standard treatments for ovarian cancer are debulking surgery combined with platinum chemotherapy drugs to prolong the survival of patients. According to clinical trials run by the American Society of Gynecologic Oncology, patients who received intraperitoneal (IP) chemotherapy survived longer on average than patients who received intravenous chemotherapy alone. Thus, intraperitoneal chemotherapy is a new potential approach for treating ovarian cancer patients. However, the toxicities and undesirable complications of IP chemotherapy are the major challenges of this treatment approach. This article helps nurses recognize the toxicities and complications of IP chemotherapy and may be used as reference for future revisions to patient care guidelines.

1. Almadrones, L.(2007).Evidence-based research for intraperitoneal chemotherapy in epithelial ovarian cancer.Clinical Journal of Oncology Nursing,11,211-216.
2. Anderson, N. J.,Hacker, E. D.(2008).Fatigue in women receiving intraperitoneal chemotherapy for ovarian cancer: A review of contributing factors.Clinical Journal of Oncology Nursing,12(3),445-454.
3. Armstrong, D. K.,Bundy, B.,Wenzel, L.,Huang, H. Q.,Baergen, R.,Lele, S.,Burger, R. A.(2006).Intraperitoneal cisplatin and paclitaxel in ovarian cancer.New England Journal of Medicine,354(1),34-43.
4. Burges, A.,Schmalfeldt, B.(2011).Ovarian cancer: Diagnosis and treatment.Deutsches Ärzteblatt International,108(38),635-641.
5. Dedrick, R. L.,Myers, C. E.,Bungay, P. M.,DeVita, V. T., Jr.(1978).Pharmacokinetic rationale for peritoneal drug administration in the treatment of ovarian cancer.Cancer Treatment Reports,62(1),1-11.
6. deNaurois, J.,Novitzky-Basso, I.,Gill, M. J.,Marti, F. M.,Cullen, M. H.,Roila, F.,ESMO Guidelines Working Group(2010).Management of febrile neutropenia: ESMO clinical practice guidelines.Annals Oncology,21(5, Suppl.),v252-v256.
7. Drake, B.(2009).Intraperitoneal chemotherapy: A reemerging approach in the treatment of ovarian cancer.Journal of Infusion Nursing,32(6),314-322.
8. Helm, C. W.(2012).Ports and complications for intraperitoneal chemotherapy delivery.BJOG: An International Journal of Obstetrics & Gynecology,119(2),150-159.
9. Hydzik, C.(2007).Implementation of intraperitoneal chemotherapy for the treatment of ovarian cancer.Clinical Journal of Oncology Nursing,11(2),221-225.
10. Lanceley, A.,Fitzgerald, D.,Jones, V.,Miles, T.,Elliott, E.,Darragh, L.,Peck, L.(2011).Ovarian cancer: Symptoms, treatment and long-term patient management.Primary Health Care,21(7),31-38.
11. Marin, K.,Oleszewski, K.,Muehlbauer, P.(2007).Intraperitoneal chemotherapy: Implications beyond ovarian cancer.Clinical Journal of Oncology Nursing,11(6),881-889.
12. Naumann, R. W.,Sukumvanich, P.,Edwards, R. P.(2009).Practice patterns of intraperitoneal chemotherapy in women with ovarian cancer.Gynecologic Oncology,114(1),37-41.
13. Rebbeck, T. R.,Kauff, N. D.,Domchek, S. M.(2009).Meta-analysis of risk reduction estimates associated with risk-reducing salpingo-oophorectomy in BRCA1 or BRCA2 mutation carriers.JNCI: Journal of the National Cancer Institute,101(2),80-87.
14. Ryan, M.,Duggan, J.(2010).Intraperitoneal chemotherapy in the treatment of ovarian cancer: Background and nursing management.Australian Journal of Cancer Nursing,11(1),11-16.
15. Sun, V.,Otis-Green, S.,Morgan, R.,Wakabayashi, M.,Hakim, A.,Callado, M. E.,Grant, M.(2013).Toxicities, complications, and clinical encounters during intraperitoneal chemotherapy in 17 women with ovarian cancer.European Journal of Oncology Nursing,17(3),375-380.
16. Teefey, P.,Zgheib, N. B.,Apte, S. M.,Gonzalez-Bosquet, J.,Judson, P. L.,Roberts, W. S.,Wenham, R. M.(2013).Factors associated with improved toxicity and tolerability of intraperitoneal chemotherapy in advanced-stage epithelial ovarian cancers.American Journal of Obstetrics & Gynecology,208(6),501.e1-501.e7.
17. Visovsky, C.,Collins, M.,Abbott, L.,Aschenbrenner, J.,Hart, C.(2007).Putting evidence into practice: Evidence-based interventions for chemotherapy-induced peripheral neuropathy.Clinical Journal of Oncology Nursing,11(6),901-913.
18. 李耀泰, Y. T.,陳福民, F. M.,朱益志, Y. C.,郭宗正, T. C.(2007)。表皮性卵巢癌之腹腔內化學治療。中華民國婦癌醫學雜誌，2，32-37。
19. 洪敏瑛, M. Y.,邱文姿, W. T.,陳淑娟, S. C.,戴仕卿, S. C.,蕭逸美, Y. M.(2011)。癌症病人嗜中性白血球低下臨床照護指引。腫瘤護理雜誌，11，41-60。
20. 徐昌鴻, C. H.(2009)。化學治療藥物所引起的神經病變。腫瘤護理雜誌，9(1)，1-12。
21. 臺灣癌症臨床研究合作組織=Taiwan Cooperative Oncology Group(2011).子宮頸癌篩檢、子宮頸癌、子宮內膜癌、上皮性卵巢癌臨床指引.台北市=Taipei City, Taiwan, ROC:國家衛生研究院=National Health Research Institutes.
22. 衛生福利部（2013，6月4日）．中華民國一百零一年死因結果摘要表．取自http://www.mohw.gov.tw/cht/DOS/DisplayStatisticFile.aspx?d=13690&s=1 [Ministry of Health and Welfare, Taiwan, ROC. (2013, June 4). Cause of death statistics: 2012. Retrieved from http://www.mohw.gov.tw/cht/DOS/DisplayStatisticFile.aspx?d=13690&s=1]

1. 陳冠媚,呂麗戎(2023)。運用Swanson關懷理論照護一位卵巢癌術後婦女之護理經驗。領導護理，24(1)，127-141。
2. 李慈萱,李昂璉(2018)。照護一位卵巢癌末期病人之護理經驗。腫瘤護理雜誌，18(2)，35-46。
3. 魏雅雯,謝馥矯,楊雪婷,王乙茜(2021)。一位未婚女性罹患卵巢癌之照護經驗。領導護理，22(2)，80-95。
4. 徐任萱(2020)。一位腹膜癌年輕女性之照護經驗。新臺北護理期刊，22(2)，109-117。
5. 張芳瑜,邱婉婷(2020)。照護一位初次診斷卵巢癌婦女不確定感之護理經驗。中科大學報，7(1)，49-65。